P
JAZZ icon

&Partners’s Jazz Pharmaceuticals JAZZ Stock Holding History

&Partners’s Portfolio JAZZ Stock Details JAZZ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$522K Buy
2,760
+127
+5% +$22.2K ﹤0.01% 1670
2025
Q4 		$448K Sell
2,633
-1,944
-42% -$298K ﹤0.01% 1676
2025
Q3 		$603K Sell
4,577
-300
-6% -$36K ﹤0.01% 1345
2025
Q2 		$517K Buy
4,877
+872
+22% +$94.7K ﹤0.01% 1339
2025
Q1 		$493K Buy
4,005
+333
+9% +$43.4K 0.01% 1139
2024
Q4 		$443K Buy
+3,672
New +$433K 0.01% 1128

Other funds holding JAZZ

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
LSV Asset Management
LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

&Partners's JAZZ Position: Q1 2026 in Review

&Partners increased its Jazz Pharmaceuticals (JAZZ) stake by 4.8% in Q1 2026, buying an estimated $22.2K and bringing the position to 2,760 shares worth $522K. The position accounts for ﹤0.01% of the portfolio, ranked #1670.

&Partners first reported a position in JAZZ in Q4 2024 and has held it in 6 quarters since. The position peaked at $603K in Q3 2025. 570 funds tracked by Wall St. Rank hold JAZZ as of Q1 2026.

  • &Partners held 2,760 shares of Jazz Pharmaceuticals worth $522K as of Q1 2026.
  • &Partners bought 127 Jazz Pharmaceuticals shares in Q1 2026, an estimated $22.2K.
  • Jazz Pharmaceuticals made up ﹤0.01% of &Partners's portfolio in Q1 2026, its #1670 holding.
  • &Partners first reported a position in Jazz Pharmaceuticals in Q4 2024 and has held it in 6 quarters since.
  • &Partners's Jazz Pharmaceuticals position peaked at $603K in Q3 2025.
  • 570 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q1 2026.

Based on &Partners's 13F filing for Q1 2026, filed 15 May 2026.